Sellas Life Sciences is trading 7.04% down at $9.67 as uncertainty ahead of the REGAL topline readout weighs on shares. - The Phase 3 REGAL trial reached its 80th event on October 28, triggering final analysis; the company has not disclosed efficacy results. - October 30 coverage described the stock as continuing a difficult month for biotech shares, while the broader biotech ETF was nearly flat for October. - No new company announcement dated October 30 was identified.